2023-09-12 13:05:23 ET
More on Exelixis
- Seeking Alpha’s Quant Rating on Exelixis
- Historical earnings data for Exelixis
- Financial information for Exelixis
- Exelixis: Predominantly Single Molecule Cancer Franchise (Rating Downgrade)
- Exelixis: Positive Advanced Pancreatic/Extra-Pancreatic Neuroendocrine Tumor Data Brings 2 Big Catalysts On Deck
- Exelixis: Long-Term Problem Isn't Shareholder Activism - It's Cabo Patent Expiry
- Exelixis, Inc. ( EXEL ) Q2 2023 Earnings Call Transcript
- Exelixis reports positive results for Cabometyx in pancreatic cancer type
- Exelixis lead product hits main goal in Phase 3 prostate cancer trial
- Exelixis, Teva settle patent dispute over cancer drug Cabometyx
For further details see:
Exelixis inks licensing deal with Insilico for tumor candidate